Yili Chen

Yili Chen


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Heart Rhythm
Verified
Journal Article
Open access
WKWulamiding Kaisaier
Wulamiding Kaisaier
ZXZixuan Xu
Zixuan Xu
LGLinjuan Guo
Linjuan Guo
YDYugang Dong
Yugang Dong
YCYili Chen
Yili Chen
WZWengen Zhu
Wengen Zhu
Left atrial appendage closure (LAAC) is primarily indicated for stroke prevention in patients with atrial fibrillation (AF) who have contraindications to long-term oral anticoagulants (OACs). However, the long-term comparative benefits of LAAC vs OACs in the broader AF population remain unclear. To study aimed to assess the long-term efficacy and safety of LAAC compared with OACs in patients with AF, we conducted a meta-analysis of randomized controlled trials (RCTs). We systematically searched PubMed, Embase, and Cochrane Library for eligible RCTs. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using fixed-effects models. Four RCTs involving 3116 patients with AF (1736 assigned to LAAC and 1380 to OACs) and follow-up durations ranging from 36 to 49.6 months were included. Compared with OACs, LAAC was associated with reduced risks of all-cause death (RR = 0.78; 95% CI: 0.64-0.95) and cardiovascular or unexplained death (RR = 0.69; 95% CI: 0.51-0.94). There were no significant differences between the 2 groups in stroke or systemic embolism, ischemic stroke, or systemic embolism, and non-cardiovascular death. LAAC was associated with significantly lower risk of hemorrhagic stroke (RR = 0.34; 95% CI: 0.16-0.76) and non-procedural clinically relevant bleeding (RR = 0.49; 95% CI: 0.40-0.61). Major bleeding (including procedural and non-procedural) risk did not differ significantly between groups. In this meta-analysis of RCTs, LAAC was associated with significantly lower risks of all-cause and cardiovascular death, hemorrhagic stroke, and non-procedural clinically relevant bleeding compared with OACs, without increasing the risk of thromboembolic events or major bleeding. These findings support the consideration of LAAC as an alternative to OAC in selected patients with AF.

28 February 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
YHYanchuang Han
Yanchuang Han
TDTailai Du
Tailai Du
SGSiyao Guo
Siyao Guo
LWLu Wang
Lu Wang
GDGang Dai
Gang Dai
ZHZhan-Peng Huang
Zhan-Peng Huang
Enhancement of protein synthesis from mRNA translation is one of the key steps supporting cardiomyocyte hypertrophy during cardiac remodeling. The methyltransferase-like5 (METTL5), which catalyzes m6A modification of 18S rRNA at position A1832, has been shown to regulate the efficiency of mRNA translation during the differentiation of ES cells and the growth of cancer cells. It remains unknown whether and how METTL5 regulates cardiac hypertrophy. In this study, we have generated a mouse model, METTL5-cKO, with cardiac-specific depletion of METTL5 in vivo. Loss function of METTL5 promotes pressure overload-induced cardiomyocyte hypertrophy and adverse remodeling. The regulatory function of METTL5 in hypertrophic growth of cardiomyocytes was further confirmed with both gain- and loss-of-function approaches in primary cardiomyocytes. Mechanically, METTL5 can modulate the mRNA translation of SUZ12, a core component of PRC2 complex, and further regulate the transcriptomic shift during cardiac hypertrophy. Altogether, our study may uncover an important translational regulator of cardiac hypertrophy through m6A modification.

1 November 2017 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YCYili Chen
Yili Chen
CCCong Chen
Cong Chen
BDBin Dong
Bin Dong
FXFuwei Xing
Fuwei Xing
HHHuiling Huang
Huiling Huang
YDYugang Dong
Yugang Dong

12 September 2017 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
RWRui Wang
Rui Wang
BMBiqi Mei
Biqi Mei
XLXinlong Liao
Xinlong Liao
XLXia Lu
Xia Lu
LYLulu Yan
Lulu Yan
TYTianhui You
Tianhui You
To determine the factors affecting the in-hospital prognosis of patients with acute ST segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI), and to establish its prognostic discriminant model. A total of 701 consecutive STEMI patients undergoing PCI were enrolled in this study. The patients were divided into two groups, good prognosis and poor prognosis, based on whether the patient had adverse outcomes (death or heart function ≥ grade III) at discharge. Demographic and basic clinical characteristics, diagnosis at admission (e.g., ventricular function, complications, or hyperlipidemia), and biomedical indicators (e.g., blood count, basal metabolism and biochemical composition, blood lipid and glucose levels, myocardial biomarkers, and coagulation) were collected and analyzed. We determined 22 factors as risk factors for the in-hospital prognosis of STEMI patients after PCI: age, cardiac function during hospitalization, complications, history of diabetes mellitus, et al., among which the history of diabetes, uric acid, urea nitrogen, and activated partial thromboplastin time (APTT) were independent risk factors. We identified four independent risk factors for the in-hospital prognosis of STEMI patients after PCI and generated a prognostic model to predict the adverse outcomes of these patients.

11 November 2022 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
XZXieyu Zhang
Xieyu Zhang
XZXinwen Zhang
Xinwen Zhang
YYYue Yang
Yue Yang
KZKai Zhi
Kai Zhi
YCYili Chen
Yili Chen
WCWei Cao
Wei Cao

18 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
YCYunjiu Cheng
Yunjiu Cheng
HDHai Deng
Hai Deng
HWHui-Qiang Wei
Hui-Qiang Wei
WLWei‐Dong Lin
Wei‐Dong Lin
ZLZhuomin Liang
Zhuomin Liang
ZWZexuan Wu
Zexuan Wu
Background: Atrial fibrillation (AF) significantly increases the ischemic stroke risk. However, the relationship between age at diagnosis of AF and subsequent stroke risk remains poorly understood. Methods and Results: We analyzed data from 5 prospective cohorts: ARIC (Atherosclerosis Risk in Communities) study, CHS (Cardiovascular Health Study), CARDIA (Coronary Artery Risk Development in Young Adults), MESA (Multi‐Ethnic Study of Atherosclerosis), and Framingham Heart Study (including Offspring cohort and the Third‐Generation cohorts). Cox regression models and competing risk survival analyses were used to assess incidence rates and hazard ratios (HRs) for ischemic stroke stratified by age groups. Among 47 239 participants (median follow‐up: 21.1 years), 6689 (14.2%) developed AF, and 536 (8.0%) subsequently experienced ischemic stroke. Younger age at AF diagnosis was significantly associated with a higher ischemic stroke risk. Fully adjusted HRs for ischemic stroke were 5.35 (95% CI, 3.56–8.03), 2.99 (95% CI, 2.32–3.86), 2.13 (95% CI, 1.75–2.58), and 1.93 (95% CI, 1.59–2.34) for AF diagnosed at ages 55, 65, 75, and 85, respectively. Compared with participants without AF at age 55, HRs for ischemic stroke were 7.30 (95% CI, 3.27–16.31) for AF diagnosed >10 years earlier, 4.98 (95% CI, 2.99–8.29) for 6 to 10 years earlier, and 4.60 (95% CI, 1.48–14.34) for ≤5 years earlier ( P ‐trend <0.001). The presence of AF yielded a 13.9 years earlier occurrence of ischemic stroke among those with AF diagnosis at 55 years compared with 1.5 years earlier at age 85. Conclusions: Younger age at AF diagnosis was associated with a higher risk of subsequent ischemic stroke.